ProBiotics - Immune Support - Gut Health
Our high-performance, custom blend of shelf-stable probiotics to support your body's natural, healthy
microbiome (gut flora) with Inulin (a prebiotic) to help the probiotics flourish and Serrapeptase
(a potent enzyme) to help create a clean environment for the friendly flora to thrive in.
Bacillus Clausii: (Alkalihalobacillus clausii) A shelf-stable, spore-forming bacillus that lives in the soil but is also a natural microbiota throughout the GI tract of mammals.
Bacillus Coagulans: Also known as Lactobacillus Sporogenes and Weizmannia coagulans: is a spore-forming, "good" bacteria (probiotic) that is able to go dormant during harsh conditions allowing it to survive in an environment that may kill off other forms of probiotics.
L. Reuteri: Limosilactobacillus reuteri, previously known as Lactobacillus reuteri, is a type of "good" bacteria (probiotic) normally found in the digestive tract. Studies have shown l. reuteri increases the amount of the immune cells, Treg cells, in the intestines which can then be absorbed back into the blood to benefit the rest of the body.
L. Rhamnosus: One of the most well studied "friendly or good" bacteria (probiotic) found in the intestines. May help in these situations:
Inulin: A dietary fiber, inulin is found in many fruits, vegetables and herbs. Most commonly made from soaking chicory roots in hot water. Inulin is a type of Prebiotic: meaning it stays in the bowel and acts as nourishment (food) for the "friendly" probiotic bacteria to grow and colonize.[6] It is also used to balance water content in the bowel which can help normalize both constipation and diarrhea.
Serrapeptase: A potent enzyme, serrapeptase is included in our Floracopia™ to create a "clean" environment for the probiotics to thrive by:
Below, please find research articles and study abstracts that further detail the benefits of some of the active ingredients in Floracopia™.*
These studies have been sourced and linked to from online medical research sites. If you'd like to learn more, please click HERE and search by ingredient name.
Disclaimer: This section is for educational purposes only. There is no guarantee the product will have these same benefits for everyone. Individual results may vary.*
Lactobacillus reuteri (L. reuteri) is a well-studied probiotic bacterium that can colonize a large number of mammals. In humans, L. reuteri is found in different body sites, including the gastrointestinal tract, urinary tract, skin, and breast milk. The abundance of L. reuteri varies among different individuals. Several beneficial effects of L. reuteri have been noted. First, L. reuteri can produce antimicrobial molecules, such as organic acids, ethanol, and reuterin. Due to its antimicrobial activity, L. reuteri is able to inhibit the colonization of pathogenic microbes and remodel the commensal microbiota composition in the host. Second, L. reuteri can benefit the host immune system. For instance, some L. reuteri strains can reduce the production of pro-inflammatory cytokines while promoting regulatory T cell development and function. Third, bearing the ability to strengthen the intestinal barrier, the colonization of L. reuteri may decrease the microbial translocation from the gut lumen to the tissues. Microbial translocation across the intestinal epithelium has been hypothesized as an initiator of inflammation. Therefore, inflammatory diseases, including those located in the gut as well as in remote tissues, may be ameliorated by increasing the colonization of L. reuteri. Notably, the decrease in the abundance of L. reuteri in humans in the past decades is correlated with an increase in the incidences of inflammatory diseases over the same period of time. Direct supplementation or prebiotic modulation of L. reuteri may be an attractive preventive and/or therapeutic avenue against inflammatory diseases.
Keywords: Lactobacillus reuteri, probiotic, microbiota, immune system, inflammatory diseases
Read the full article here
The decline of circulating testosterone levels in aging men is associated with adverse health effects. During studies of probiotic bacteria and obesity, we discovered that male mice routinely consuming purified lactic acid bacteria originally isolated from human milk had larger testicles and increased serum testosterone levels compared to their age-matched controls. Further investigation using microscopy-assisted histomorphometry of testicular tissue showed that mice consuming Lactobacillus reuteri in their drinking water had significantly increased seminiferous tubule cross-sectional profiles and increased spermatogenesis and Leydig cell numbers per testis when compared with matched diet counterparts This showed that criteria of gonadal aging were reduced after routinely consuming a purified microbe such as L. reuteri. We tested whether these features typical of sustained reproductive fitness may be due to anti-inflammatory properties of L. reuteri, and found that testicular mass and other indicators typical of old age were similarly restored to youthful levels using systemic administration of antibodies blocking pro-inflammatory cytokine interleukin-17A. This indicated that uncontrolled host inflammatory responses contributed to the testicular atrophy phenotype in aged mice. Reduced circulating testosterone levels have been implicated in many adverse effects; dietary L. reuteri or other probiotic supplementation may provide a viable natural approach to prevention of male hypogonadism, absent the controversy and side-effects of traditional therapies, and yield practical options for management of disorders typically associated with normal aging. These novel findings suggest a potential high impact for microbe therapy in public health by imparting hormonal and gonad features of reproductive fitness typical of much younger healthy individuals.
Read the full study here:
Aim: We aimed to evaluate the efficacy of a synbiotic containing Bacillus Coagulans in treatment of IBS.
Background: Some studies have shown the efficacy of probiotics in the treatment of irritable bowel syndrome (IBS).
Patients and methods: Adult IBS patients (n=85) were randomized to receive a synbiotic containing Bacillus Coagulans or placebo for 12 weeks. Frequency of IBS symptoms including abdominal pain (scored 1 to 7), and diarrhea and constipation (scored 1 to 5) was evaluated before and after the intervention and then after nine months follow-up.
Results: Twenty-three patients in the synbiotic group and 33 patients in the placebo group completed the study (age = 39.8±12.7 years, 78.6% female). After treatment, more reduction in abdominal pain frequency was observed with synbiotic compared with placebo (score reduction 4.2±1.8 vs. 1.9±1.5, P<0.001). Diarrhea frequency was decreased in the synbiotic group, but not in the placebo group (score reduction 1.9±1.2 vs. 0.0±0.5, P<0.001). Decrease in constipation frequency was the same between the two groups (score reduction 0.9±1.2 vs. 0.8±1.1, P=0.561). After nine months follow-up, abdominal pain frequency was decreased (P=0.016), constipation frequency was increased (P<0.001), and diarrhea frequency remained unchanged in the synbiotic group (P=1.000). In the placebo group, abdominal pain frequency was increased (P<0.001), constipation frequency remained unchanged (P=0.553), and diarrhea frequency was increased (P<0.001).
Conclusion: Bacillus Coagulans improves abdominal pain and diarrhea in IBS patients. Further studies on a larger sample of patients are warranted.
Custom Keyword Group: Irritable bowel syndrome, Probiotics, Prebiotics, Synbiotics, Therapy
From a total of 123 patients who referred to the gastroenterology clinic during the study period, 15 patients did not fulfill the inclusion criteria and 23 patients were not willing to participate. Eighty-five patients who fulfilled the inclusion criteria were randomized into the synbiotic (n = 41) and placebo (n = 44) groups and received the interventions. Seventeen patients in the synbiotic group discontinued the study (12 patients due to vomiting and 5 patients due to diarrhea) and one patient was lost during the follow-up. In the placebo group, 11 patients discontinued the study; 5 patients due to constipation, 3 patients due to urticaria and 3 patients due to bloating. Dropout rates were then 41.4% in the synbiotic group compared with 25% in the placebo group (P = 0.083). Fifty-six patients completed the study all of them were fully adherent to the treatment; 23 patients in the synbiotic and 33 patients in the placebo group (Figure 1). Mean age was 39.8±12.7 years, and 45 (78.6%) cases were female. The two groups were not significantly different regarding demographic and disease characteristics (Table 1).
Read the entire Study here.
Inulin, a soluble dietary fiber, is widely found in more than 36 000 plant species as a reserve polysaccharide. The primary sources of inulin, include Jerusalem artichoke, chicory, onion, garlic, barley, and dahlia, among which Jerusalem artichoke tubers and chicory roots are often used as raw materials for inulin production in the food industry. It is universally acknowledged that inulin as a prebiotic has an outstanding effect on the regulation of intestinal microbiota via stimulating the growth of beneficial bacteria. In addition, inulin also exhibits excellent health benefits in regulating lipid metabolism, weight loss, lowering blood sugar, inhibiting the expression of inflammatory factors, reducing the risk of colon cancer, enhancing mineral absorption, improving constipation, and relieving depression. In this review paper, we attempt to present an exhaustive overview of the function and health benefits of inulin.
Metabolic syndrome (MetS) is a difficult-to-manage disease that poses a significant risk to human health. Here, we show that the supplementation of Lactobacillus reuteri ZJ617 ameliorates symptoms of MetS in mice induced by the high-fat diet. L. reuteri ZJ617 modulates host metabolism by interacting with the microbiome, resulting in the production of spermidine synthesized by the microbiota. L. reuteri ZJ617 serves as a source of substrates for the microbiota to synthesize spermidine, hence preventing the decline of bacteria responsible for spermidine production. Spermidine treatment mimics the metabolic effects of L. reuteri ZJ617, whereas pharmacological inhibition of spermidine biosynthesis in mice abolishes these benefits. Our findings reveal the mechanism by which L. reuteri ZJ617 alleviates MetS symptoms and provide support for its potential use as a probiotic for promoting metabolic health.
© 2025. The Author(s).
Background: Dysbiosis and antibiotic-associated diarrhea (AAD) are significant concerns in clinical settings. Probiotics, such as Bacillus clausii (O/C, N/R, SIN, T), a spore-forming bacterium resistant to gastrointestinal conditions and most commonly used antibiotics, emerge as a promising approach. We aim to assess the role of B. clausii in preventing AAD in children and adults during antibiotic therapy. Materials and methods: A systematic literature search was conducted across multiple databases, including MEDLINE, EMBASE, Cochrane Library, LILACS, and SciELO, up to May 2024. Studies were included if they involved B. clausii (O/C, N/R, SIN, T) administration during antibiotic treatment and reported AAD-related outcomes. Results: A total of four studies were included in the review. The studies comprised two randomized controlled trials (RCTs), one meta-analysis of RCTs, and one expert consensus. The primary outcome was the effectiveness of B. clausii (O/C, N/R, SIN, T) in reducing the incidence of diarrhea. Results showed a significant reduction in the risk of AAD and gastrointestinal symptoms in patients receiving it at a dosage of 4 × 109 CFU/day for children and 6 × 109 CFU/day for adolescents and adults for up to 14 days. Conclusions: B. clausii (O/C, N/R, SIN, T) appears to be an effective probiotic for preventing AAD in adults and children. It significantly improves gastrointestinal symptoms associated with antibiotic treatment, including diarrhea, nausea, and epigastric pain. Future studies are recommended to further elucidate its effectiveness in diverse populations, especially in low- and middle-income countries.
Keywords: Bacillus clausii; antibiotic-associated diarrhea; dysbiosis; probiotics; systematic review.
Background and aim: Helicobacter pylori is one of the most common pathogenic bacteria in the human gut, and is also one of the most important factors that cause digestive disorders such as chronic inflammation, gastric ulcers, and even gastric cancer. Since the use of various antibiotics to treat H. pylori infection is associated with the development of resistance in this bacterium, the aim of this study was to determine the anti-H. pylori effects of Lactobacillus acidophilus, L. plantarum, and L. rhamnosus in the stomach tissue of C57BL/6 mice.
Materials and methods: In this experimental study, 70 mice in ten groups were evaluated from July to September 2017 in the microbiology laboratory of the School of Medicine, Alborz University of Medical Sciences, Karaj, Iran. After induction of H. pylori infection in mice with the standard strain of H. pylori (ATCC 43504), the infected mice were treated with drug and Lactobacillus species in different groups. Then, the anti-H. pylori effects of lactobacilli were evaluated by stool antigen test and tissue staining.
Results: Based on ELISA results and histological findings, a reduction of inflammation was observed. The group which was only exposed to L. rhamnosus and the one which was exposed to all three strains of Lactobacillus showed the highest antimicrobial effect on H. pylori.
Conclusion: According to the results of this study, probiotic bacteria including L. acidophilus, L. plantarum, and L. rhamnosus could be useful in the reduction of H. pylori infection in the mouse model.
Keywords: Gastritis; Helicobacter pylori; Lactobacillus; Probiotic.
Copyright © 2019 by S. Karger AG, Basel.
Background: The possibility of using microbes to maintain health, and to prevent or treat disease is a topic as old as microbiology. The research of novel probiotic strains is important in order to satisfy the increasing request of the market and to obtain functional products in which the probiotic cultures are more active and with better probiotic characteristics than those already present on the market.
Aim of the study: In this study, the probiotic potential of Lactobacillus strains isolated from Italian elderly human faeces was investigated.
Methods: The Lactobacillus strains were identified and examined for resistance to gastric acidity and bile toxicity, adhesion to HT-29 cells, antimicrobial activities, antibiotic susceptibility and plasmid profile. Survival of the strains through human intestine was examined in a 3 months human feeding trial.
Results: Two strains, Lactobacillus rhamnosus IMC 501 and Lactobacillus paracasei IMC 502, tolerated well low pH and bile acids. In antimicrobial activity assays, both strains showed inhibitory properties towards selected potential harmful microorganisms, particularly against Candida albicans. The two selected strains expressed high in vitro adherence to HT-29 cells increasing this characteristic when they are used in combination and they were resistant to vamcomycin, colistin sulphate, gentamicin, oxolinic acid and kanamycin. Moreover, the two strains could be recovered from stools of volunteers after the feeding trials.
Conclusions: Lactobacillus rhamnosus IMC 501 and L. paracasei IMC 502 present favourable strain-specific properties for their utilisation as probiotics in functional foods and the high adhesion ability of the L. rhamnosus IMC 501 and L. paracasei IMC 502 used in combination, confirmed by both in vitro and in vivo study, indicate that the two bacterial strains could be used as health-promoting bacteria.
Office Hours:
When We Ship:
How We Ship
Within the USA:
International Shipping:
You may return most new, unopened items within 30 days of delivery for a refund of the purchase price less a 15% restocking fee and any shipping charges. The return item(s) must be in their original condition (unopened and unused) and accompanied by a copy of the original order form/packing list.
For health and safety reasons, we are unable to accept returns of personal care items such as lotions or creams.
No returns or refunds on unsealed (ie: opened) items, creams and books. No exceptions!
If you need to return an item, please contact us with your order number and details about the product you would like to return. We will respond quickly with a Return Authorization (RA) number and instructions for how to return the items. Returned items without a RA number will not be processed.
Items can be returned via any carrier you choose. We recommend you send the items insured, signature required.
Please mail to:
WAM Essentials, Inc; 320 Grant Ave; Strawn; TX 76475
Please see below for answers to some commonly asked questions.
In the event that you receive your package and it is missing an item or includes an incorrect item, we must be contacted within three (3) business days of receipt of the package for resolution/ answers. No refund/return can be issued if more than three (3) business days pass without an attempt to contact us.
If you have a questions about packing (ie: safety seals, mfg vs expiration dates, lid liners, etc), we must be contacted within three (3) business days of receipt of the package for resolution/ answers. No refund/return can be issued if more than three (3) business days pass without an attempt to contact us.
Please see below for the most commonly asked questions about Floracopia™. We will continually add more FAQs to this as more questions come in to us.
The probiotics we've chosen for our Floracopia™ are shelf stable and are mostly resistant to the harsh environment of the stomach. However, if you'd like to ensure optimal colonizing unit availability, it's perfectly okay to refrigerate the bottle once you receive it.
Yes. In fact, Dr. Wong recommends taking a probiotic with antibiotic use to help protect the good flora in the gut. Plus, the Bacillus Clausii and the Bacillus Coagulans are recommended for use during some antibiotic use.
Dr. Wong's Essentials
Dr. Wong's Essentials® Candessence® is an important tool to help maintain a proper balance of good bacteria and yeast in the GI Tract.* Each container of Candessence® contains: Cream of...